Immunotherapy for food and latex allergy

Allergens and Allergen Immunotherapy, Fourth Edition

Volumn , Issue , 2008, Pages 429-446

  Nowak Wegrzyn, Anna ^a   Sicherer, Scott H ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLERGEN; RECOMBINANT PROTEIN;

ALLERGY; ANIMAL; DESENSITIZATION; FOOD ALLERGY; HUMAN; IMMUNOLOGY; ORAL DRUG ADMINISTRATION; REVIEW; SUBCUTANEOUS DRUG ADMINISTRATION; SUBLINGUAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ADMINISTRATION, SUBLINGUAL; ALLERGENS; ANIMALS; DESENSITIZATION, IMMUNOLOGIC; FOOD HYPERSENSITIVITY; HUMANS; INJECTIONS, SUBCUTANEOUS; LATEX HYPERSENSITIVITY; RECOMBINANT PROTEINS;

EID: 58149467317     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (100)

1. Sicherer SH, Sampson HA. 9. Food allergy. J Allergy Clin Immunol 2006; 117(2 suppl Mini-Primer): S470-S475.
2. Yocum MW, Butterfield JH, Klein JS, et al. Epidemiology of anaphylaxis in Olmested County: a population-based study. J Allergy Clin Immunol 1999; 104: 452-456.
3. Sicherer SH, Munoz-Furlong A, Sampson HA. Prevalence of peanut and tree nut allergy in the United States determined by means of a random digit dial telephone survey: a 5-year follow-up study. J Allergy Clin Immunol 2003; 112(6): 1203-1207.
4. Munoz-Furlong A, Sampson HA, Sicherer SH. Prevalence of self-reported seafood allergy in the US. J Allergy Clin Immunol 2004; 113: S100.
5. Sicherer SH. Clinical implications of cross-reactive food allergens. J Allergy Clin Immunol 2001; 108(6): 881-890.
6. Wood RA. The natural history of food allergy. Pediatrics 2003; 111(6 pt 3): 1631-1637.
7. Fleischer DM, Conover-Walker MK, Matsui EC, et al. The natural history of tree nut allergy. J Allergy Clin Immunol 2005; 116(5): 1087-1093.
8. Grundy J, Matthews S, Bateman B, et al. Rising prevalence of allergy to peanut in children: data from 2 sequential cohorts. J Allergy Clin Immunol 2002; 110(5): 784-789.
9. Bock SA, Munoz-Furlong A, Sampson HA. Fatalities due to anaphylactic reactions to foods. J Allergy Clin Immunol 2001; 107(1): 191-193.
10. Taylor JS, Erkek E. Latex allergy: diagnosis and management. Dermatol Ther 2004; 17(4): 289-301.
11. Oppenheimer JJ, Nelson HS, Bock SA, et al. Treatment of peanut allergy with rush immunotherapy. J Allergy Clin Immunol 1992; 90(2): 256-262.
12. Nelson HS, Lahr J, Rule R, et al. Treatment of anaphylactic sensitivity to peanuts by immunotherapy with injections of aqueous peanut extract. J Allergy Clin Immunol 1997; 99(6 pt 1): 744-751.
13. Valenta R, Kraft D. Type I allergic reactions to plant-derived food: a consequence of primary sensitization to pollen allergens. J Allergy Clin Immunol 1996; 97: 895.
14. Asero R. Effects of birch pollen-specific immunotherapy on apple allergy in birch pollenhypersensitive patients. Clin Exp Allergy 1998; 28: 1368-1373.
15. Asero R. How long does the effect of birch pollen injection SIT on apple allergy last? Allergy 2003; 58(5): 435-438.
16. Bucher X, Pichler WJ, Dahinden CA, et al. Effect of tree pollen specific, subcutaneous immunotherapy on the oral allergy syndrome to apple and hazelnut. Allergy 2004; 59(12): 1272-1276.
17. Bolhaar ST, Tiemessen MM, Zuidmeer L, et al. Efficacy of birch-pollen immunotherapy on crossreactive food allergy confirmed by skin tests and double-blind food challenges. Clin Exp Allergy 2004; 34(5): 761-769.
18. Alonso R, Enrique E, Pineda F, et al. An observational study on outgrowing food allergy during non-birch pollen-specific, subcutaneous immunotherapy. Int Arch Allergy Immunol 2007; 143(3): 185-189.
19. Kinaciyan T, Jahn-Schmid B, Radakovics A, et al. Successful sublingual immunotherapy with birch pollen has limited effects on concomitant food allergy to apple and the immune response to the Bet v 1 homolog Mal d 1. J Allergy Clin Immunol 2007; 119(4): 937-943.
20. Asero R. Effects of birch pollen SIT on apple allergy: a matter of dosage? Allergy 2004; 59(12): 1269-1271.
21. Bohle B, Radakovics A, Luttkopf D, et al. Characterization of the T cell response to the major hazelnut allergen, Cor a 1.04: evidence for a relevant T cell epitope not cross-reactive with homologous pollen allergens. Clin Exp Allergy 2005; 35(10): 1392-1399.
22. Rolinck-Werninghaus C, Staden U, Mehl A, et al. Specific oral tolerance induction with food in children: transient or persistent effect on food allergy? Allergy 2005; 60(10): 1320-1322.
23. Niggemann B, Staden U, Rolinck-Werninghaus C, et al. Specific oral tolerance induction in food allergy. Allergy 2006; 61(7): 808-811.
24. Ko J, Mayer L. Oral tolerance: lessons on treatment of food allergy. Eur J Gastroenterol Hepatol 2005; 17(12): 1299-1303.
25. Patriarca G, Nucera E, Roncallo C, et al. Oral desensitizing treatment in food allergy: clinical and immunological results. Aliment Pharmacol Ther 2003; 17(3): 459-465.
26. Meglio P, Bartone E, Plantamura M, et al. A protocol for oral desensitization in children with IgEmediated cow’s milk allergy. Allergy 2004; 59(9): 980-987.
27. Buchanan AD, Green TD, Jones SM, et al. Egg oral immunotherapy in nonanaphylactic children with egg allergy. J Allergy Clin Immunol 2007; 119(1): 199-205.
28. Calvani M, Sopo SM. Exercise-induced anaphylaxis caused by wheat during specific oral tolerance induction. Ann Allergy Asthma Immunol 2007; 98(1): 98-99.
29. Caminiti L, Passalacqua G, Vita D, et al. Food-exercise-induced anaphylaxis in a boy successfully desensitized to cow milk. Allergy 2007; 62(3): 335-336.
30. Patriarca C, Romano A, Venuti A, et al. Oral specific hyposensitization in the management of patients allergic to food. Allergol Immunopathol (Madr) 1984; 12(4): 275-281.
31. Shenassa MM, Perelmutter L, Gerarrd JW. Desensitization to peanut. J Allergy Clin Immunol 1985; 75: 177S.
32. Patriarca G, Schiavino D, Nucera E, et al. Food allergy in children: results of a standardized protocol for oral desensitization 1. Hepatogastroenterology 1998; 45(19): 52-58.
33. Bauer A, Ekanayake MS, Wigger-Alberti W, et al. Oral rush desensitization to milk. Allergy 1999; 54(8): 894-895.
34. Nucera E, Schiavino D, D’Ambrosio C, et al. Immunological aspects of oral desensitization in food allergy. Dig Dis Sci 2000; 45(3): 637-641.
35. Rueff F, Eberlein-Konig B, Przybilla B. Oral hyposensitization with celery juice. Allergy 2001; 56(1): 82-83.
36. Patriarca G, Nucera E, Pollastrini E, et al. Oral rush desensitization in peanut allergy: a case report. Dig Dis Sci 2006; 51(3): 471-473.
37. Buchanan AD, Scurlock AM, Jone SM, et al. Oral desensitization and induction of tolerance in peanut-allergic children. J Allergy Clin Immunol 2006; 117(2): S327.
38. Mansfield L. Successful oral desensitization for systemic peanut allergy. Ann Allergy Asthma Immunol 2006; 97(2): 266-267.
39. Morisset M, Moneret-Vautrin DA, Guenard L, et al. Oral desensitization in children with milk and egg allergies obtains recovery in a significant proportion of cases. A randomized study in 60 children with cow’s milk allergy and 90 children with egg allergy. Allerg Immunol (Paris) 2007; 39(1): 12-19.
40. Mempel M, Rakoski J, Ring J, et al. Severe anaphylaxis to kiwi fruit: Immunologic changes related to successful sublingual allergen immunotherapy. J Allergy Clin Immunol 2003; 111(6): 1406-1409.
41. Kerzl R, Simonowa A, Ring J, et al. Life-threatening anaphylaxis to kiwi fruit: protective sublingual allergen immunotherapy effect persists even after discontinuation. J Allergy Clin Immunol 2007; 119(2): 507-508.
42. Enrique E, Pineda F, Malek T, et al. Sublingual immunotherapy for hazelnut food allergy: a randomized, double-blind, placebo-controlled study with a standardized hazelnut extract. J Allergy Clin Immunol 2005; 116(5): 1073-1079.
43. De Boissieu D, Dupont C. Sublingual immunotherapy for cow’s milk protein allergy: a preliminary report. Allergy 2006; 61(10): 1238-1239.
44. Valenta R, Vrtala S, Laffer S, et al. Recombinant allergens. Allergy 1998; 53(6): 552-561.
45. Reuter A, Lidholm J, Andersson K, et al. A critical assessment of allergen component-based in vitro diagnosis in cherry allergy across Europe. Clin Exp Allergy 2006; 36(6): 815-823.
46. Bolhaar ST, Zuidmeer L, Ma Y, et al. A mutant of the major apple allergen, Mal d 1, demonstrating hypo-allergenicity in the target organ by double-blind placebo-controlled food challenge. Clin Exp Allergy 2005; 35(12): 1638-1644.
47. Astier C, Morisset M, Roitel O, et al. Predictive value of skin prick tests using recombinant allergens for diagnosis of peanut allergy. J Allergy Clin Immunol 2006; 118(1): 250-256.
48. Li XM, Schofield BH, Huang CK, et al. A murine model of IgE-mediated cow’s milk hypersensitivity. J Allergy Clin Immunol 1999; 103(2 pt 1): 206-214.
49. Li XM, Serebrisky D, Lee SY, et al. A murine model of peanut anaphylaxis: T- and B-cell responses to a major peanut allergen mimic human responses. J Allergy Clin Immunol 2000; 106(1 pt 1): 150-158.
50. Li X, Huang CK, Schofield BH, et al. Strain-dependent induction of allergic sensitization caused by peanut allergen DNA immunization in mice. J Immunol 1999; 162(5): 3045-3052.
51. Roy K, Mao HQ, Huang SK, et al. Oral gene delivery with chitosan-DNA nanoparticles generates immunologic protection in a murine model of peanut allergy. Nat Med 1999; 5(4): 387-391.
52. Srivastava K, Li XM, Bannon GA, et al. Investigation of the use of ISS-linked Ara h2 for the treatment of peanut-induced allergy. J Allergy Clin Immunol 2001; 107: S233 (abstract).
53. Nguyen MD, Cinman N, Yen J, et al. DNA-based vaccination for the treatment of food allergy. Allergy 2001; 56(suppl 67): 127-130.
54. Burks AW, Cockrell G, Stanley JS, et al. Recombinant peanut allergen Ara h I expression and IgE binding in patients with peanut hypersensitivity. J Clin Invest 1995; 96(4): 1715-1721.
55. Stanley JS, King N, Burks AW, et al. Identification and mutational analysis of the immunodominant IgE binding epitopes of the major peanut allergen Ara h 2. Arch Biochem Biophys 1997; 342(2): 244-253.
56. Rabjohn P, Helm EM, Stanley JS, et al. Molecular cloning and epitope analysis of the peanut allergen Ara h 3. J Clin Invest 1999; 103(4): 535-542.
57. Bannon GA, Cockrell G, Connaughton C, et al. Engineering, characterization and in vitro efficacy of the major peanut allergens for use in immunotherapy. Int Arch Allergy Immunol 2001; 124(1-3): 70-72.
58. King N, Helm R, Stanley JS, et al. Allergenic characteristics of a modified peanut allergen. Mol Nutr Food Res 2005; 49(10): 963-971.
59. Swoboda I, Bugajska-Schretter A, Linhart B, et al. A recombinant hypoallergenic parvalbumin mutant for immunotherapy of IgE-mediated fish allergy. J Immunol 2007; 178(10): 6290-6296.
60. Vrtala S, Hirtenlehner K, Susani M, et al. Genetic engineering of a hypoallergenic trimer of the major birch pollen allergen Bet v 1. FASEB J 2001; 15(11): 2045-2047.
61. Reese G, Ballmer-Weber BK, Wangorsch A, et al. Allergenicity and antigenicity of wild-type and mutant, monomeric, and dimeric carrot major allergen Dau c 1: destruction of conformation, not oligomerization, is the roadmap to save allergen vaccines. J Allergy Clin Immunol 2007; 119(4): 944-951.
62. Srivastava KD, Li XM, King N, et al. Immunotherapy with modified peanut allergens in a murine model of peanut allergy. J Allergy Clin Immunol 2002; 109: S287.
63. Yeung VP, Gieni RS, Umetsu DT, et al. Heat-killed Listeria monocytogene as an adjuvant converts established murine TH2-dominated immune responses into TH1-dominated responses. J Immunol 1998; 161: 4146-4152.
64. Frick OL, Bachanan BB, Delval G, et al. Allergen immunotherapy with heat-killed Listeria monocytogenes as adjuvant prevents allergeic reactions in highly sensitized dogs. J Allergy Clin Immunol 2001; 107: S232 (abstract).
65. Li XM, Srivastava K, Huleatt JW, et al. Engineered recombinant peanut protein and heat-killed Listeria monocytogenes coadministration protects against peanut-induced anaphylaxis in a murine model. J Immunol 2003; 170(6): 3289-3295.
66. Li XM, Srivastava K, Grishin A, et al. Persistent protective effect of heat-killed Escherichia coli producing “engineered,” recombinant peanut proteins in a murine model of peanut allergy. J Allergy Clin Immunol 2003; 112(1): 159-167.
67. Leung DY, Sampson HA, Yunginger JW, et al. Effect of anti-IgE therapy in patients with peanut allergy. N Engl J Med 2003; 348(11): 986-993.
68. Li XM. Traditional Chinese herbal remedies for asthma and food allergy. J Allergy Clin Immunol 2007; 120: 25-31.
69. Hsieh KY, Hsu CI, Lin JY, et al. Oral administration of an edible-mushroom-derived protein inhibits the development of food-allergic reactions in mice. Clin Exp Allergy 2003; 33(11): 1595-1602.
70. Lee SY, Huang CK, Zhang TF, et al. Oral administration of IL-12 suppresses anaphylactic reactions in a murine model of peanut hypersensitivity. Clin Immunol 2001; 101(2): 220-228.
71. Garabrant DH, Roth HD, Parsad R, et al. Latex sensitization in health care workers and in the US general population. Am J Epidemiol 2001; 153(6): 515-522.
72. Slater JE. Latex allergens. Clin Allergy Immunol 2004; 18: 369-386.
73. Banerjee B, Kanitpong K, Fink JN, et al. Unique and shared IgE epitopes of Hev b 1 and Hev b 3 in latex allergy. Mol Immunol 2000; 37(12-13): 789-798.
74. Raulf-Heimsoth M, Chen Z, Rihs HP, et al. Analysis of T-cell reactive regions and HLA-DR4 binding motifs on the latex allergen Hev b 1 (rubber elongation factor). Clin Exp Allergy 1998; 28(3): 339-348.
75. Palomares O, Villalba M, Quiralte J, et al. 1,3-beta-glucanases as candidates in latex-pollen-vegetable food cross-reactivity. Clin Exp Allergy 2005; 35(3): 345-351.
76. Bohle B, Wagner B, Vollmann U, et al. Characterization of T cell responses to Hev b 3, an allergen associated with latex allergy in spina bifida patients. J Immunol 2000; 164(8): 4393-4398.
77. de Silva HD, Sutherland MF, Suphioglu C, et al. Human T-cell epitopes of the latex allergen Hev b 5 in health care workers. J Allergy Clin Immunol 2000; 105(5): 1017-1024.
78. Drew AC, Eusebius NP, Kenins L, et al. Hypoallergenic variants of the major latex allergen Hev b 6.01 retaining human T lymphocyte reactivity. J Immunol 2004; 173(9): 5872-5879.
79. Karisola P, Mikkola J, Kalkkinen N, et al. Construction of hevein (Hev b 6.02) with reduced allergenicity for immunotherapy of latex allergy by comutation of six amino acid residues on the conformational IgE epitopes. J Immunol 2004; 172(4): 2621-2628.
80. Karisola P, Kotovuori A, Poikonen S, et al. Isolated hevein-like domains, but not 31-kd endochitinases, are responsible for IgE-mediated in vitro and in vivo reactions in latex-fruit syndrome. J Allergy Clin Immunol 2005; 115(3): 598-605.
81. Wagner S, Breiteneder H, Simon-Nobbe B, et al. Hev b 9, an enolase and a new cross-reactive allergen from hevea latex and molds. Purification, characterization, cloning and expression. Eur J Biochem 2000; 267(24): 7006-7014.
82. Wagner S, Sowka S, Mayer C, et al. Identification of a Hevea brasiliensis latex manganese superoxide dismutase (Hev b 10) as a cross-reactive allergen. Int Arch Allergy Immunol 2001; 125(2): 120-127.
83. Yeang HY, Cheong KF, Sunderasan E, et al. The 14.6 kd rubber elongation factor (Hev b 1) and 24 kd (Hev b 3) rubber particle proteins are recognized by IgE from patients with spina bifida and latex allergy. J Allergy Clin Immunol 1996; 98(3): 628-639.
84. Yeang HY, Arif SA, Raulf-Heimsoth M, et al. Hev b 5 and Hev b 13 as allergen markers to estimate the allergenic potency of latex gloves. J Allergy Clin Immunol 2004; 114(3): 593-598.
85. Pereira C, Rico P, Lourenco M, et al. Specific immunotherapy for occupational latex allergy. Allergy 1999; 54(3): 291-293.
86. Nucera E, Schiavino D, Pollastrini E, et al. Desensitization to latex by percutaneous route. J Investig Allergol Clin Immunol 2002; 12(2): 134-135.
87. Pereira C, Pedro E, Tavares B, et al. Specific immunotherapy for severe latex allergy. Allerg Immunol (Paris) 2003; 35(6): 217-225.
88. Leynadier F, Herman D, Vervloet D, et al. Specific immunotherapy with a standardized latex extract versus placebo in allergic healthcare workers. J Allergy Clin Immunol 2000; 106(3): 585-590.
89. Sastre J, Fernandez-Nieto M, Rico P, et al. Specific immunotherapy with a standardized latex extract in allergic workers: a double-blind, placebo-controlled study. J Allergy Clin Immunol 2003; 111(5): 985-994.
90. Sastre J, Raulf-Heimsoth M, Rihs HP, et al. IgE reactivity to latex allergens among sensitized healthcare workers before and after immunotherapy with latex. Allergy 2006; 61(2): 206-210.
91. Tabar AI, Anda M, Bonifazi F, et al. Specific immunotherapy with standardized latex extract versus placebo in latex-allergic patients. Int Arch Allergy Immunol 2006; 141(4): 369-376.
92. Patriarca G, Nucera E, Pollastrini E, et al. Sublingual desensitization: a new approach to latex allergy problem. Anesth Analg 2002; 95(4): 956-960.
93. Cistero BA, Sastre J, Enrique E, et al. Tolerance and effects on skin reactivity to latex of sublingual rush immunotherapy with a latex extract. J Investig Allergol Clin Immunol 2004; 14(1): 17-25.
94. Nettis E, Colanardi MC, Soccio AL, et al. Double-blind, placebo-controlled study of sublingual immunotherapy in patients with latex-induced urticaria: a 12-month study. Br J Dermatol 2007; 156(4): 674-681.
95. Antico A, Pagani M, Crema A. Anaphylaxis by latex sublingual immunotherapy. Allergy 2006; 61(10): 1236-1237.
96. Bernardini R, Campodonico P, Burastero S, et al. Sublingual immunotherapy with a latex extract in paediatric patients: a double-blind, placebo-controlled study. Curr Med Res Opin 2006; 22(8): 1515-1522.
97. Rolland JM, Drew AC, O’hehir RE. Advances in development of hypoallergenic latex immunotherapy. Curr Opin Allergy Clin Immunol 2005; 5(6): 544-551.
98. Arif SA, Hamilton RG, Yusof F, et al. Isolation and characterization of the early nodule-specific protein homologue (Hev b 13), an allergenic lipolytic esterase from Hevea brasiliensis latex. J Biol Chem 2004; 279(23): 23933-23941.
99. Yip L, Hickey V, Wagner B, et al. Skin prick test reactivity to recombinant latex allergens. Int Arch Allergy Immunol 2000; 121(4): 292-299.
100. de Silva HD, Gardner LM, Drew AC, et al. The hevein domain of the major latex-glove allergen Hev b 6.01 contains dominant T cell reactive sites. Clin Exp Allergy 2004; 34(4): 611-618.